Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.59 | N/A | -0.17% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.59 | N/A | -0.17% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed cautious optimism about their ongoing research initiatives. They did not provide specific guidance for future quarters.
Management highlighted ongoing research efforts and potential future developments.
They emphasized the importance of their current projects in the pipeline.
Beam Therapeutics reported an EPS of $0.59, slightly missing expectations. The stock reacted negatively, declining by 0.78%. The lack of revenue data and guidance may have contributed to investor uncertainty.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SEAGATE TECHNOLOGY H
Oct 28, 2013